Last reviewed · How we verify
Axitinib Tablets
Axitinib is a selective inhibitor of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3).
Axitinib is a selective inhibitor of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3). Used for Advanced renal cell carcinoma.
At a glance
| Generic name | Axitinib Tablets |
|---|---|
| Sponsor | Nanjing Leads Biolabs Co.,Ltd |
| Drug class | tyrosine kinase inhibitor |
| Target | VEGFR-1, VEGFR-2, VEGFR-3 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
By inhibiting these receptors, axitinib blocks the formation of new blood vessels that tumors need to grow and spread, thereby slowing tumor progression.
Approved indications
- Advanced renal cell carcinoma
Common side effects
- Hypertension
- Fatigue
- Diarrhea
Key clinical trials
- A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma (PHASE2)
- Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma (PHASE2)
- Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) (PHASE3)
- Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) (PHASE1, PHASE2)
- Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer (PHASE3)
- Prior Axitinib as a Determinant of Outcome of Renal Surgery (PHASE2)
- A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma (PHASE1)
- Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Axitinib Tablets CI brief — competitive landscape report
- Axitinib Tablets updates RSS · CI watch RSS
- Nanjing Leads Biolabs Co.,Ltd portfolio CI